• FirefoxUpgrade to the new Firefox »
  •  Dow Up1.69% Nasdaq Up2.12%

    InSite Vision Incorporated (INSV)

    -Other OTC
    0.21 0.00(0.00%) 3:30PM EST
    Add to Portfolio
    ProfileGet Profile for:
    InSite Vision Incorporated
    965 Atlantic Avenue
    Alameda, CA 94501
    United States - Map
    Phone: 510-865-8800
    Fax: 510-865-5700
    Website: http://www.insitevision.com

    Index Membership:N/A
    Industry:Drug Delivery
    Full Time Employees:31

    Business Summary 

    InSite Vision Incorporated, an ophthalmic product development company, develops ophthalmic pharmaceutical products to address unmet eye care needs in the United States. It is developing products based on its proprietary DuraSite drug delivery technology. The company’s lead products comprise AzaSite, a macrolide antibiotic for the treatment of bacterial conjunctivitis; and Besivance, a fluoroquinolone antibiotic for the treatment of bacterial conjunctivitis. Its products also include ISV-101, a formulation with a low concentration of bromfenac for the treatment of dry eye disease. In addition, the company is involved in preparing a new drug application for the commercial approval of BromSite by the U.S. Food & Drug Administration for the prevention of pain and inflammation associated with ocular surgery; and advancing AzaSite Plus and DexaSite through Phase III clinical studies for the treatment of eye infections. Further, it has a pipeline of earlier-stage product candidates based on its platform technologies. The company has collaborative, licensing, and service agreements with Pfizer and Pfizer Products, Inc.; Akorn Pharmaceuticals; Catalent Pharma Solutions; and Bausch and Lomb Incorporated. InSite Vision Incorporated was founded in 1986 and is based in Alameda, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on InSite Vision Incorporated

    Key Executives 
    Mr. Timothy Ruane M.B.A., 49
    Chief Exec. Officer, Director and Member of Officer Equity Grant Committee
    Mr. Louis C. Drapeau B.S., M.B.A., 70
    Chief Financial Officer, Principal Accounting Officer, VP and Member of Officer Equity Grant Committee
    Mr. Surendra I. Patel , 59
    VP of Operations and Quality
    Dr. Lyle M. Bowman Ph.D., 65
    VP of Devel. and Sec.
    Dr. Kamran Hosseini M.D., Ph.D., 49
    Chief Medical Officer, VP of Clinical Affairs, VP of Clinical & Regulatory Affairs and Member of Scientific Advisory Board
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders